 
- 积分
- 385
- 威望
- 385
- 包包
- 1381
|
Scientists have inserted mRNA into mesenchymal stem cells (MSCs) to produce a drug-delivery vehicle. Following systemic administration, the modified MSCs targeted and adhered to sites of inflammation, then released interleukin-10 that significantly reduced local swelling.
+ ]' Y; Z+ K' u( [4 M
3 X, r4 E4 v4 c1 L, FHistorically, MSC-based treatments have had mixed results. MSCs exert their therapeutic effects in hit-and-run style. That is, MSCs are rapidly cleared after entering the bloodstream, typically within a few hours or days. Yet, despite the transience of MSC therapeutic action, a team of scientists reports that it has engineered MSCs that rapidly localized at a distant site of inflammation in an in vivo model, and delivered therapeutically relevant concentrations of the drug. The MSCs had been engineered enhanced homing and the expression of interleukin-10, which is not inherently produced by MSCs.
0 m2 r9 T4 d. |0 a: T+ [" I1 I$ v1 M8 z
The team of scientists included members representing Brigham and Women’s Hospital, the Harvard Stem Cell Institute, MIT, and Massachusetts General Hospital. The team, which published the results of its proof-of concept study in the October 3 issue of Blood, notes that its work is already drawing interest from biopharmaceutical companies.
$ q" Q5 o, g, |0 t8 s4 N2 f6 Q7 `0 {
“This opens the door to thinking of mRNA transfection of cell populations as next-generation therapeutics in the clinic, as they get around some of the delivery challenges that have been encountered with biological agents,” said Oren Levy, Ph.D., co-lead author of the study and instructor of medicine in the laboratory of research leader Jeffrey Karp, Ph.D. Dr. Karp, a Harvard Stem Cell Institute principal faculty member and associate professor at the Brigham and Women's Hospital, is also affiliated with Harvard Medical School and MIT.4 d" N6 p: G; K
% o; E* F+ G, S6 V6 N“If you think of a cell as a drug factory, what we’re doing is targeting cell-based, drug factories to damaged or diseased tissues, where the cells can produce drugs at high enough levels to have a therapeutic effect,” said Dr. Karp.$ {' Y Q3 a4 w! X. t
! i6 t* D- U+ k# ^7 f* q
The key to success was the use of triple-transfected MSCs. In addition to expressing interleukin-1-, the cells expressed, in the team’s words, “functional rolling machinery.” This machinery consisted of P-selectin glycoprotein ligand-1(PSGL-1) and Sialyl-Lewisx (SLeX). Basically, the cells expressed both the immunomodulating agent and adhesive surface proteins.
8 X& [" f3 F8 D" V# R) ?! w |
-
总评分: 威望 + 2
包包 + 10
查看全部评分
|